戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                  No adverse events occurred.
2                                           A total of 93 PFS events occurred.
3  episodes of serious hypoglycaemia or other serious adverse events occurred.
4                    During follow-up, 10,648 suicide-related events occurred.
5 s of follow-up (44152 person-years), 405 CHD and 228 stroke events occurred.
6 the placebo group, but no significant study-related adverse events occurred.
7                                       A total of 75% of VTE events occurred after hospital discharge, with a 19.5-day med
8                                  A few drug-related adverse events occurred and were similar across groups.
9                              Two unexpected serious adverse events occurred, both for the first patient enrolled.
10 atients; and apixaban, 12886 patients), 4770 major bleeding events occurred during 447037 person-quarters with NOAC presc
11                In this study, extreme rainfall and snowfall events occurred during a 3-year field experiment, allowing us
12                                       Major adverse cardiac events occurred in 1.1% and 4.2% of everolimus-treated and CN
13                          Treatment-emergent serious adverse events occurred in 103 (7%) women in the neratinib group and
14                                             Serious adverse events occurred in 11% of the patients who received inclisira
15                                        Drug-related adverse events occurred in 130 (24%) of 531 participants in the once
16                                             Immune-mediated events occurred in 14 (12%) patients.
17                         Grade 3-4 treatment-related adverse events occurred in 14 (37%) patients in the ipilimumab every-
18                               A total of 38 serious adverse events occurred in 15 patients (5 events were adjudicated as
19                                             Serious adverse events occurred in 15% of the patients in the group that rece
20                                             Serious adverse events occurred in 19 patients (33%) in the surgery group, in
21                                         Severe hypoglycemia events occurred in 2 participants in each group.
22                                             Serious adverse events occurred in 2 patients in the IFN group, in 1 patient
23              In-hospital major adverse cardiac and cerebral events occurred in 2.0% in fTRA and 2.9% in TFA (P=0.40).
24                  Grade 3 or worse treatment-related adverse events occurred in 21 (8%) of 249 patients, the most common o
25                                                     Adverse events occurred in 21 of 23 (91%) control patients, 19 of 22
26                                               Minor adverse events occurred in 22% of patients in the control group and n
27                  Grade 3 or worse treatment-related adverse events occurred in 23 (13%) of 184 patients; the most common
28                                        52 grade 3-4 adverse events occurred in 27 (46%) of 59 patients in the eltrombopag
29                                Drug-related serious adverse events occurred in 28 (38%) of 74 patients.
30 pericardial effusions, but serious procedure/device-related events occurred in 3 patients (8.6%) within 24 h, and 8 patie
31                                        ADR-associated major events occurred in 3.4% (n=10/292).
32                                           Grade 3-4 adverse events occurred in 37 (76%) of 49 patients; most common were
33                                        Five serious adverse events occurred in 4 cases (15%), including pulmonary hemorrh
34                                        Grade 3 to 5 adverse events occurred in 47% of the patients in the combination gro
35                         Grade 3-4 treatment-related adverse events occurred in 48 (18%) of 270 patients-most commonly gra
36                                        Grade 3 or 4 adverse events occurred in 5 (MVC), 13 (MVC-FTC), 9 (MVC-TDF), and 8
37                                                     Adverse events occurred in 51 (48%) of CGM participants and 43 (40%)
38                                             Serious adverse events occurred in 6% of patients in the control group vs non
39                                             Serious adverse events occurred in 75 (19%) patients in the ceftazidime-aviba
40                                 Severe (grade >/=3) adverse events occurred in 84% of neutropenia (32%), alanine transami
41 o groups, and only grade 1 (mild) local or systemic adverse events occurred in both groups.
42                                       Eight serious adverse events occurred in each group.
43 in one who received placebo, and adjudicated cardiovascular events occurred in five who received tofacitinib and in none
44                                                Most adverse events occurred in the first day after vaccination, and were
45          Radiocarbon dating indicates that the three burial events occurred in the last 2000 calendar years.
46 er between treatment groups, although some specific adverse events occurred more often in the intensive group.
47 = 2) occurred in more than 1 patient; the remaining adverse events occurred only once.
48 eek after the administration of vaccine or placebo, adverse events occurred significantly more often with the active vacc
49                                       Three serious adverse events occurred that were unrelated to the vaccine.
50                                                        Most events occurred within the first month postpartum (35 of 50).

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。
 
コーパス検索結果について
ご利用ガイド
ご利用規定
新規対訳・お問い合わせ
Copyright 1993 - ライフサイエンス辞書プロジェクト